Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRMANASDAQ:ONCONASDAQ:PLRZNYSE:TMBR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$0.71-3.0%$0.77$0.66▼$5.00$4.54M0.571.18 million shs32,711 shsONCOOnconetix$4.73-24.9%$6.11$4.27▼$1,190.00$305.30M3.5102,989 shs302,077 shsPLRZPolyrizon$0.84-22.0%$57.85$0.55▼$1,200.00$4.45MN/A1.50 million shs1.77 million shsTMBRTimber Pharmaceuticals$1.87$0.32▼$3.39$1.21M0.03511,937 shs26,307 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics-2.96%-4.40%-8.56%-40.14%-76.34%ONCOOnconetix-24.90%-24.90%-40.04%-56.56%-99.07%PLRZPolyrizon-21.96%+3.86%-73.49%-99.40%+83,499,900.00%TMBRTimber Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRMADermata Therapeutics3.0428 of 5 stars3.55.00.00.03.60.00.6ONCOOnconetix0.3449 of 5 stars0.04.00.00.02.00.00.0PLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ATMBRTimber PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRMADermata Therapeutics 3.00Buy$3.00321.17% UpsideONCOOnconetix 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ATMBRTimber Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TMBR, ONCO, PLRZ, and DRMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRMADermata TherapeuticsN/AN/AN/AN/A$24.24 per shareN/AONCOOnconetix$2.52M120.95N/AN/A$3.01 per share1.57PLRZPolyrizonN/AN/AN/AN/AN/AN/ATMBRTimber Pharmaceuticals$80K0.00N/AN/A$1.79 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRMADermata Therapeutics-$7.80M-$16.41N/A∞N/AN/A-247.39%-179.72%8/6/2025 (Estimated)ONCOOnconetix-$37.41MN/A0.00∞N/A-2,758.89%N/A-48.09%8/27/2025 (Estimated)PLRZPolyrizonN/AN/A0.00∞N/AN/AN/AN/AN/ATMBRTimber Pharmaceuticals-$19.38MN/A0.00N/AN/AN/A-511.45%-180.93%N/ALatest TMBR, ONCO, PLRZ, and DRMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 million5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRMADermata TherapeuticsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ATMBRTimber PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRMADermata TherapeuticsN/A3.443.44ONCOOnconetixN/A0.060.05PLRZPolyrizonN/AN/AN/ATMBRTimber PharmaceuticalsN/A0.500.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRMADermata Therapeutics8.67%ONCOOnconetix23.89%PLRZPolyrizonN/ATMBRTimber Pharmaceuticals3.62%Insider OwnershipCompanyInsider OwnershipDRMADermata Therapeutics9.40%ONCOOnconetix3.10%PLRZPolyrizonN/ATMBRTimber Pharmaceuticals1.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRMADermata Therapeutics86.38 million1.85 millionNot OptionableONCOOnconetix1264.55 million57.17 millionN/APLRZPolyrizonN/A5.33 millionN/AN/ATMBRTimber Pharmaceuticals93.43 million3.38 millionNot OptionableTMBR, ONCO, PLRZ, and DRMA HeadlinesRecent News About These CompaniesMSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sourcesJanuary 31, 2025 | nypost.comTimber back in Dutch squad and twin brother also called upAugust 30, 2024 | reuters.comRare disease drug from LEO's Timber felled by failed studyAugust 25, 2024 | pharmaphorum.comCan timber construction overcome its growing pains?May 13, 2024 | reuters.comTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual MeetingMarch 10, 2024 | businesswire.comTimber Pharmaceuticals Announces Official Name ChangeJanuary 28, 2024 | msn.comTimber Pharmaceuticals Inc (TMBRQ)January 13, 2024 | uk.investing.comTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketNovember 29, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)November 29, 2023 | finance.yahoo.comTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | tmcnet.comTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | finance.yahoo.comMVST, FBIO and VTVT among mid-day moversNovember 21, 2023 | seekingalpha.comTimber Pharmaceuticals files for Chapter 11 in wake of failed mergerNovember 17, 2023 | msn.comTimber Pharma slips ahead of shareholder vote on mergerNovember 16, 2023 | msn.comTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceSeptember 18, 2023 | finance.yahoo.comHC Wainwright Downgrades Timber PharmaceuticalsAugust 29, 2023 | 247wallst.comHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)August 28, 2023 | msn.comTimber Pharmaceuticals rockets as it agrees to a takeoverAugust 21, 2023 | thepharmaletter.comTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 21, 2023 | benzinga.comDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike HigherAugust 21, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTMBR, ONCO, PLRZ, and DRMA Company DescriptionsDermata Therapeutics NASDAQ:DRMA$0.71 -0.02 (-2.96%) Closing price 06/13/2025 03:47 PM EasternExtended Trading$0.72 +0.01 (+1.08%) As of 06/13/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Onconetix NASDAQ:ONCO$4.73 -1.57 (-24.90%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.78 +0.04 (+0.95%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Polyrizon NASDAQ:PLRZ$0.84 -0.24 (-21.96%) As of 06/13/2025 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.Timber Pharmaceuticals NYSE:TMBRTimber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
